EcoDrugPlus

Angiotensin I Converting Enzyme

Ensembl ID : ENSODEG00000007071
Gene Symbol: ACE
1 Cross references
93 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSODEG00000019590
Gene Symbol: AGTR1
3 Cross references
206 Possible Orthologues:

Apelin Receptor

Ensembl ID : ENSODEG00000011407
Gene Symbol: APLNR
3 Cross references
171 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSODEG00000011643
Gene Symbol: APH1A
3 Cross references
137 Possible Orthologues:

Aph-1 Homolog B, Gamma-Secretase Subunit

Ensembl ID : ENSODEG00000016784
Gene Symbol: APH1B
3 Cross references
191 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSODEG00000001703
Gene Symbol: APEX1
2 Cross references
210 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s Type

Ensembl ID : ENSODEG00000017256
Gene Symbol: ALOX12
3 Cross references
200 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSODEG00000005645
Gene Symbol: ALOX5AP
3 Cross references
200 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSODEG00000001671
Gene Symbol: AVPR1A
3 Cross references
264 Possible Orthologues:

Arginine Vasopressin Receptor 1b

Ensembl ID : ENSODEG00000006394
Gene Symbol: AVPR1B
3 Cross references
134 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSODEG00000005166
Gene Symbol: AVPR2
3 Cross references
231 Possible Orthologues:

Aryl Hydrocarbon Receptor

Ensembl ID : ENSODEG00000006823
Gene Symbol: AHR
3 Cross references
154 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).